DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.
A webcast of both events will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
Conference Details:
Event: |
|
|
Oppenheimer 32nd Annual Virtual Healthcare Conference |
Date: |
|
|
March 14, 2022 |
Time: |
|
|
11:00 am ET |
Format: |
|
|
Fireside chat: AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape |
Participants: |
|
|
RA Session II, President, Founder and CEO |
|
|
|
|
Date: |
|
|
March 15, 2022 |
Time: |
|
|
1:20 pm ET |
Format: |
|
|
Fireside chat |
Participants: |
|
|
RA Session II, President, Founder and CEO |
|
|
|
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D |
|
|
|
Kamran Alam, Chief Financial Officer |
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
